Cancer and Leukemia Group B is emerging from a clinical trials group focused on testing multiple chemotherapeutic regimens to a more selected modular concept of therapy development. Current emphasis is on answering dose intensity questions and exploring the important scientific contributions of cytogenetics, immunology and molecular biology in an effort to improve the therapy of neoplastic diseases. Our emphasis continues in the areas of lymphoma, myeloma, breast cancer, leukemia, and respiratory cancer. Bowman Gray has chaired two major studies in the lymphomas consisting of CALGB protocol #8451 and 8452. These studies are designed to test the relative effectiveness of various drugs used in the treatment of lymphomas. Results of these two studies provided the development of the successor protocol, CALGB #8556, which is AMOPLACE. Evaluation of these studies will allow us to determine the relative role of adriamycin, whether given initially or sequentially, and further explore the importance of initial intensive combination therapy versus alternating noncross-resistant treatments. Pilot studies have demonstrated the effectiveness of these treatments in refractory Hodgkin's disease and this modular concept of combination chemotherapy has been extended to a pilot study, CALGB #8654. Bowman Gray chairs CALGB #8514, a randomized study comparing melphalan/prednisone treatment with or without alpha 2 in newly diagnosed myeloma patients. One hundred forty-six patients have accrued to this study since October 4, 1985. Pilot studies at Bowman Gray involving the combination of high-dose cytosine arabinoside and mitoxantrone will provide important information to be utilized by the group in developing subsequent leukemic studies. Our laboratory interest in drug resistance should provide important clues in the development of more effective treatments for acute leukemia. Our commitment to CALGB protocol studies is demonstrated by our accrual of 169 patients in 1986.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wake Forest University Health Sciences
Schools of Medicine
United States
Zip Code
Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7

Showing the most recent 10 out of 209 publications